Layer-specific myocardial strain for early detection of anthracycline-induced cardiotoxicity: the CARDIAC-STRAIN prospective diagnostic study protocol
Anthracyclines remain cornerstone agents in oncology, yet their cardiotoxic potential poses a substantial clinical challenge. Up to 30% of treated patients develop some degree of cardiac dysfunction, with overt heart failure occurring in 2–5% of cases. Current surveillance relies on serial ejection fraction measu...